Needham & Co. Raises PT on Cantel Medical (CMN) to $33

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Following the company's positive earnings report yesterday, Needham & Company maintained a Buy rating on Cantel Medical (NYSE: CMN) and raised its price target to $33.00 (from $28.00).

Commenting on the results, analyst Dalton Chandler said, "CMN slightly missed our revenue estimate, but emphasis on new, higher margin products and focus on cost controls helped the company easily top our bottom line estimate. These improvements appear to be sustainable and could improve further."

For an analyst ratings summary and ratings history on Cantel Medical (NYSE: CMN) click here. For more ratings news on Cantel Medical click here.

Shares of Cantel Medical closed at $28.51 yesterday, with a 52 week range of $18.84-$32.78.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
• Wells Fargo Downgrades Ruby Tuesday (RT) to Market Perform
• UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Needham & Company, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?